Eloxx Pharmaceuticals

Company Overview

Snapshot

Founded in September 2013, Eloxx Pharmaceuticals operates with 11–50 employees. The company has raised a total of $98.5 million across 4 funding rounds from 10 investors. In June 2026, Eloxx Pharmaceuticals announced the pricing of a $66.0 million public offering and its uplisting to Nasdaq.

Business overview

Eloxx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases. Its platform technologies are designed to correct nonsense mutations and ribosomal mutations, which are implicated in conditions such as cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, and Alport syndrome. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving patients with these genetic disorders.

Strategic signal

In March 2024, Eloxx Pharmaceuticals entered into an exclusive agreement with Almirall to license ZKN-013 for rare dermatological diseases. This partnership signals a strategic expansion of Eloxx's pipeline beyond its core genetic disease focus, leveraging its drug development capabilities into new therapeutic areas and potentially broadening its market reach.

Company Intelligence Q&A

What was the most recent public offering by Eloxx Pharmaceuticals?

In June 2026, Eloxx Pharmaceuticals announced the pricing of a $66.0 million public offering and its uplisting to Nasdaq.

What was the outcome of the Phase 2 clinical study for Alport Syndrome with ELX-02?

In September 2023, Eloxx Pharmaceuticals reported independent confirmation of positive biopsy results in all patients treated with ELX-02 in the Phase 2 clinical study for Alport Syndrome, showing improvement in kidney morphology and reduction or stabilization of proteinuria.

What strategic partnership did Eloxx Pharmaceuticals form in March 2024?

In March 2024, Eloxx Pharmaceuticals entered into an exclusive agreement with Almirall to license ZKN-013 for rare dermatological diseases.

When did Eloxx Pharmaceuticals acquire Zikani Therapeutics?

In April 2021, Eloxx Pharmaceuticals acquired Zikani Therapeutics.

When did Eloxx Pharmaceuticals become a public company?

Eloxx Pharmaceuticals became a public company in April 2018, following a reverse merger with Sevion Therapeutics Inc. in December 2017.